- Report
- May 2023
- 391 Pages
Global
From €4621EUR$4,799USD£3,975GBP
- Report
- July 2023
- 407 Pages
Global
From €4621EUR$4,799USD£3,975GBP
- Report
- August 2023
- 120 Pages
Global
From €2311EUR$2,400USD£1,988GBP
- Report
- March 2024
- 189 Pages
Global
From €3249EUR$3,374USD£2,794GBP
€3610EUR$3,749USD£3,105GBP
- Report
- May 2024
- 182 Pages
Global
From €3249EUR$3,374USD£2,794GBP
€3610EUR$3,749USD£3,105GBP
- Report
- March 2024
- 188 Pages
Global
From €3249EUR$3,374USD£2,794GBP
€3610EUR$3,749USD£3,105GBP
- Report
- March 2024
- 196 Pages
Global
From €3249EUR$3,374USD£2,794GBP
€3610EUR$3,749USD£3,105GBP
- Report
- March 2024
- 188 Pages
Global
From €3249EUR$3,374USD£2,794GBP
€3610EUR$3,749USD£3,105GBP
- Report
- March 2024
- 191 Pages
Global
From €3249EUR$3,374USD£2,794GBP
€3610EUR$3,749USD£3,105GBP
- Report
- February 2024
- 175 Pages
Global
From €4815EUR$5,000USD£4,141GBP
- Report
- February 2024
- 250 Pages
Global
From €4815EUR$5,000USD£4,141GBP
- Report
- February 2024
- 175 Pages
Global
From €4815EUR$5,000USD£4,141GBP
- Report
- February 2024
- 175 Pages
Global
From €4815EUR$5,000USD£4,141GBP
- Report
- February 2024
- 175 Pages
Global
From €4815EUR$5,000USD£4,141GBP
- Report
- February 2024
- 175 Pages
Global
From €4815EUR$5,000USD£4,141GBP
- Report
- February 2024
- 175 Pages
Global
From €4815EUR$5,000USD£4,141GBP
- Report
- February 2024
- 250 Pages
Global
From €4815EUR$5,000USD£4,141GBP
- Report
- January 2024
- 200 Pages
Global
From €4815EUR$5,000USD£4,141GBP
- Report
- January 2024
- 200 Pages
Global
From €4815EUR$5,000USD£4,141GBP
- Report
- January 2024
- 200 Pages
Global
From €4815EUR$5,000USD£4,141GBP
BeiGene is a market within the context of Oncology Drugs, which are drugs used to treat cancer. These drugs are used to target and destroy cancer cells, while minimizing damage to healthy cells. BeiGene is a biopharmaceutical company that develops and commercializes innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company focuses on developing therapies that target cancer cells with precision and accuracy, while also providing a safe and effective treatment for patients. BeiGene's portfolio includes a range of drugs, including small molecules, antibodies, and other biologics. The company also has a pipeline of novel therapies in development.
BeiGene is one of many companies in the Oncology Drugs market. Other companies include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, and Roche. Show Less Read more